Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Interventional cardiology

A new drug-eluting stent that does not live up to its promise

Nature Reviews Cardiology volume 6, pages 500–501 (2009)Cite this article

Drug-eluting stents are an established treatment option for coronary artery disease, although they are not without their problems. The MAHOROBA® stent attempts to harness the theoretical advantages of both tacrolimus and polymer degradation, but has proved not to be effective in the treatment of de novo coronary lesions.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Roukoz, H. et al. Comprehensive meta-analysis in drug eluting stents versus bare metal stents during extended follow up. Am. J. Med. 122, 581.e1–10 (2009).

    Article  Google Scholar 

  2. Serruys, P. W., Kutryk, M. J. & Ong, A. T. Coronary-artery stents. N. Engl. J. Med. 354, 483–495 (2006).

    Article  CAS  Google Scholar 

  3. Doyle, B. et al. Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation 116, 2391–2398 (2007).

    Article  Google Scholar 

  4. Farb, A., Burke, A. P., Kolodgie, F. D. & Virmani, R. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 108, 1701–1706 (2003).

    Article  Google Scholar 

  5. Onuma, Y. et al. MAHOROBA, first-in-man study: 6-month results of a biodegradable polymer sustained release tacrolimus-eluting stent in de novo coronary stenoses. Eur. Heart J. doi:10.1093/eurheartj/ehp127

    Article  CAS  Google Scholar 

  6. Hofma, S. H. et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur. Heart J. 27, 166–170 (2006).

    Article  Google Scholar 

  7. Windecker, S. et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularization (LEADERS): a randomized non-inferiority trial. Lancet 372, 1163–1173 (2008).

    Article  CAS  Google Scholar 

  8. Cutlip, D. E. et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115, 2344–2351 (2007).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA

    David R. Holmes Jr

Authors
  1. David R. Holmes Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David R. Holmes Jr.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Holmes, D. A new drug-eluting stent that does not live up to its promise. Nat Rev Cardiol 6, 500–501 (2009). https://doi.org/10.1038/nrcardio.2009.117

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2009.117

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing